X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Global pharma venturing beyond the US - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Global pharma venturing beyond the US

Jul 9, 2010

No one can ever completely write off the US generics market. This is despite the intense competition there. After all, it is still the world's largest pharma market. And the opportunities in terms of drugs going off patent are huge. But most global players have realised that cannot entirely bank their fortunes on this highly competitive market. Opportunities elsewhere have to be explored. And in this quest for greener pastures, emerging markets and even Europe have caught the fancy of quite a lot of players. This is true of both innovators and generic companies alike.

The lure of emerging markets (or semi regulated markets)
Emerging markets have attractions for Indian and global pharma players for several reasons. Domestic companies earn revenues from branded generics in India and unbranded generics in the developed markets. But other emerging markets namely Asia, Russia, CIS, Africa and the like offer the best of both the worlds. Unlike in the US or Europe, generics here can be branded. In that respect, the environment is similar to that in India. But unlike India, medicines there are not subject to price control. And thus, the generics sold in the semi regulated markets have the potential to earn higher revenues and profits.

For innovators, emerging markets offer them the chance to shore up their sagging business. Most of their blockbuster drugs are set to lose patents over the next few years. And their pipelines are not filling up fast to counter the decline in sales. The approval process has also become tougher. Thus, not many new patented drugs are expected to hit the markets in the future. Little wonder then that venturing into emerging markets has turned out to be the obvious solution.

What are global players upto?
Global innovators are entering the emerging markets especially India. This is either through acquisitions or partnerships. For instance, Daiichi Sankyo has acquired a majority stake in Ranbaxy. GSK Plc has allied with Dr. Reddy's to sell generic products in the semi regulated markets. Pfizer has entered into a partnership with Aurobindo Pharma.

Not just innovators, top generic companies such as Teva, Mylan, and Watson have also made acquisitions in the last few years. All with the purpose of reducing their dependence on the US. Take the case of Teva. The Israeli generics player recently acquired the second largest generics company in Germany i.e., Ratiopharm. What is more, Teva plans to spend US$ 15-20 bn on acquisitions through 2015. The company aims to reduce the proportion of sales in the US from more than 60% at present to less than 50% by 2015.

Thus, while the US will continue to form an integral part of the revenues and profits of global players, the sheen now lies elsewhere, in the less explored and less regulated markets that are Asia, Africa, Russia and to some extent Latin America.


Equitymaster requests your view! Post a comment on "Global pharma venturing beyond the US". Click here!

  

More Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

More Views on News

Most Popular

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)

Apr 11, 2019

A must have checklist for every investor in the Indian stock market.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

RANBAXY LAB SHARE PRICE


Apr 1, 2015 (Close)

TRACK RANBAXY LAB

  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MARKET STATS